Arcturus Therapeutics Holdings (ARCT) Return on Capital Employed (2019 - 2026)

Arcturus Therapeutics Holdings has reported Return on Capital Employed for 8 years, with the latest figure at 39.46% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1102.0% year-over-year to 39.46%; the trailing twelve-month figure through Mar 2026 stood at 39.46% (down 1102.0% YoY), and the FY2025 full-year result was 28.12%, up 166.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 39.46%, down from 31.73% in the prior quarter.
• The five-year high for Return on Capital Employed was 20.87% in Q1 2023, with the low at 75.19% in Q1 2022.
• Historically, Return on Capital Employed has averaged 26.61% across 5 years, with a median of 28.56% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed soared 9606 bps — and 2024, when it slumped 6083 bps.
• Arcturus Therapeutics Holdings' Return on Capital Employed stood at 4.97% in 2022, then tumbled by 535 bps to 21.63% in 2023, then plunged by 52 bps to 32.78% in 2024, then gained by 3 bps to 31.73% in 2025, then dropped by 24 bps to 39.46% in 2026.
• The last three Return on Capital Employed figures came in at 39.46% (Q1 2026), 31.73% (Q4 2025), and 29.67% (Q3 2025), per Business Quant data.